Breaking News

Twitter Quarterly Profit of 2 Cents a Share Beats Estimates; Shares Surge
Tweet TWEET

News Alert: ViroPharma reinforces commitment to address medical needs and provide innovative treatment options for patients with

  News Alert: ViroPharma reinforces commitment to address medical needs and
 provide innovative treatment options for patients with adrenal insufficiency
                                    at ECE

  PR Newswire

  MAIDENHEAD, England, April 22, 2013

MAIDENHEAD, England, April 22, 2013 /PRNewswire/ --

Who:   ViroPharma, an international biopharmaceutical company committed to
developing and commercialising innovative solutions for physicians to address
the unmet medical needs of patients living with diseases that have few, if
any, clinical therapeutic options.

What: European Congress of Endocrinology, Bella Center, Copenhagen, Denmark,
27 April - 1 May

  *The ViroPharma symposium, ' A new paradigm in the treatment of patients
    with adrenal insufficiency ' , 28 April 2013, 18.30-20.00, Auditorium 15,
    will bring together an internationally renowned faculty to discuss:

       *Challenges of meeting needs of adrenal insufficiency (AI) patients
         with immediate release hydrocortisone
       *The impact of current therapies on well-being and quality of life
       *Latest research on the circadian rhythm of cortisol, including its
         importance in metabolism and cardiovascular health
       *Innovative new approaches for optimising the management of AI

  *Two posters will be presented at the ECE scientific sessions :

       *Poster 1: European Adrenal Insufficiency Registry (EU-AIR): a
         comparative observational study of glucocorticoid replacement
         therapy. Poster P49. Ekman et al.: Tuesday 30 April, 13:00-14:00 PDT,
         Poster hall.
       *Poster 2: Management of Addison's disease patients using dual release
         hydrocortisone during periods of intercurrent illness (ICI). Poster
         P24. Johannsson et al.: Monday 29 April, 13:00:14:00 PDT, Poster
         hall.

                              Symposium faculty:

Co-Chairs: Eystein Husebye, Bergen, Norway; Ulla Feldt-Rasmussen, Copenhagen,
                                   Denmark

    Panel: Eve Van Cauter, Chicago, USA; Ashley Grossman, Oxford, UK; Anna
        Nilsson, Gothenburg, Sweden; Marcus Quinkler, Berlin, Germany

                                      

For further information about ViroPharma, visit http://www.viropharma.com/

For further information about ECE, visit http://www.ece2013.org/

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing novel solutions for physician
specialists to address unmet medical needs of patients living with diseases
that have few if any clinical therapeutic options, including C1 esterase
inhibitor deficiency, treatment of prolonged, acute, convulsive seizures in
children and adolescents, adrenal insufficiency, and C. difficile infection
(CDI). Our goal is to provide rewarding careers to employees, to create new
standards of care in the way serious diseases are treated, and to build
international partnerships with the patients, advocates, and health care
professionals we serve.

Contact: ViroPharma Incorporated Contacts: Emma White (Media), PR & Advocacy
Manager, Europe, Phone +44-(0)7881-534-541